Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice.

Cesaro A, Defrêne J, Lachhab A, Pagé N, Tardif MR, Al-Shami A, Oravecz T, Fortin PR, Daudelin JF, Labrecque N, Aoudjit F, Pelletier M, Tessier PA.

PLoS One. 2019 Aug 22;14(8):e0221528. doi: 10.1371/journal.pone.0221528. eCollection 2019.

2.

Correction of lung inflammation in a F508del CFTR murine cystic fibrosis model by the sphingosine-1-phosphate lyase inhibitor LX2931.

Veltman M, Stolarczyk M, Radzioch D, Wojewodka G, De Sanctis JB, Dik WA, Dzyubachyk O, Oravecz T, de Kleer I, Scholte BJ.

Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L1000-L1014. doi: 10.1152/ajplung.00298.2016. Epub 2016 Sep 23.

3.

Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans.

Huang WC, Liang J, Nagahashi M, Avni D, Yamada A, Maceyka M, Wolen AR, Kordula T, Milstien S, Takabe K, Oravecz T, Spiegel S.

FASEB J. 2016 Aug;30(8):2945-58. doi: 10.1096/fj.201600394R. Epub 2016 Apr 29.

4.

Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases.

Donoviel MS, Hait NC, Ramachandran S, Maceyka M, Takabe K, Milstien S, Oravecz T, Spiegel S.

FASEB J. 2015 Dec;29(12):5018-28. doi: 10.1096/fj.15-274936. Epub 2015 Aug 31.

5.

Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.

Lee SC, Fujiwara Y, Liu J, Yue J, Shimizu Y, Norman DD, Wang Y, Tsukahara R, Szabo E, Patil R, Banerjee S, Miller DD, Balazs L, Ghosh MC, Waters CM, Oravecz T, Tigyi GJ.

Mol Cancer Res. 2015 Jan;13(1):174-85. doi: 10.1158/1541-7786.MCR-14-0263. Epub 2014 Aug 26.

6.

Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response.

Hu J, Oda SK, Shotts K, Donovan EE, Strauch P, Pujanauski LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G, Oravecz T, Pelanda R, Torres RM.

J Immunol. 2014 Jul 1;193(1):85-95. doi: 10.4049/jimmunol.1300429. Epub 2014 Jun 2.

7.

Genetic deletion of Mst1 alters T cell function and protects against autoimmunity.

Salojin KV, Hamman BD, Chang WC, Jhaver KG, Al-Shami A, Crisostomo J, Wilkins C, Digeorge-Foushee AM, Allen J, Patel N, Gopinathan S, Zhou J, Nouraldeen A, Jessop TC, Bagdanoff JT, Augeri DJ, Read R, Vogel P, Swaffield J, Wilson A, Platt KA, Carson KG, Main A, Zambrowicz BP, Oravecz T.

PLoS One. 2014 May 22;9(5):e98151. doi: 10.1371/journal.pone.0098151. eCollection 2014.

8.

Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.

Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, Distler A, Dees C, Maier C, Munoz L, Krönke G, Uderhardt S, Distler O, Jones S, Rose-John S, Oravecz T, Schett G, Distler JH.

Ann Rheum Dis. 2015 Jun;74(6):1317-24. doi: 10.1136/annrheumdis-2013-204401. Epub 2014 Mar 11.

PMID:
24618263
9.

Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G, Pelanda R, Torres RM.

Cancer Immunol Res. 2013 Oct;1(4):245-55. doi: 10.1158/2326-6066.CIR-13-0043-T.

10.

Integrin-α FG-GAP repeat-containing protein 2 is critical for normal B cell differentiation and controls disease development in a lupus model.

Al-Shami A, Crisostomo J, Wilkins C, Xu N, Humphries J, Chang WC, Anderson SJ, Oravecz T.

J Immunol. 2013 Oct 1;191(7):3789-98. doi: 10.4049/jimmunol.1203534. Epub 2013 Aug 30.

11.

Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine.

Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, Jhaver KG, Diacou A, Gershon MD.

Gut. 2014 Jun;63(6):928-37. doi: 10.1136/gutjnl-2013-304901. Epub 2013 Jun 7.

12.

Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B.

Rao S, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z, Jeffers JR, Rhodes M, Anderson S, Oravecz T, Hunger SP, Timakhov RA, Zhang R, Balachandran S, Zambetti GP, Testa JR, Look AT, Wiest DL.

Blood. 2012 Nov 1;120(18):3764-73. doi: 10.1182/blood-2012-03-415349. Epub 2012 Sep 13.

13.

Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors.

Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL.

J Immunol. 2011 Jul 15;187(2):664-75. doi: 10.4049/jimmunol.1100029. Epub 2011 Jun 20.

14.

S1P is associated with protection in human and experimental cerebral malaria.

Finney CA, Hawkes CA, Kain DC, Dhabangi A, Musoke C, Cserti-Gazdewich C, Oravecz T, Liles WC, Kain KC.

Mol Med. 2011;17(7-8):717-25. doi: 10.2119/molmed.2010.00214. Epub 2011 May 5.

15.

A mouse model of hereditary folate malabsorption: deletion of the PCFT gene leads to systemic folate deficiency.

Salojin KV, Cabrera RM, Sun W, Chang WC, Lin C, Duncan L, Platt KA, Read R, Vogel P, Liu Q, Finnell RH, Oravecz T.

Blood. 2011 May 5;117(18):4895-904. doi: 10.1182/blood-2010-04-279653. Epub 2011 Feb 23.

16.

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932).

Bagdanoff JT, Donoviel MS, Nouraldeen A, Carlsen M, Jessop TC, Tarver J, Aleem S, Dong L, Zhang H, Boteju L, Hazelwood J, Yan J, Bednarz M, Layek S, Owusu IB, Gopinathan S, Moran L, Lai Z, Kramer J, Kimball SD, Yalamanchili P, Heydorn WE, Frazier KS, Brooks B, Brown P, Wilson A, Sonnenburg WK, Main A, Carson KG, Oravecz T, Augeri DJ.

J Med Chem. 2010 Dec 23;53(24):8650-62. doi: 10.1021/jm101183p. Epub 2010 Nov 22.

PMID:
21090716
17.

Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development.

Al-Shami A, Jhaver KG, Vogel P, Wilkins C, Humphries J, Davis JJ, Xu N, Potter DG, Gerhardt B, Mullinax R, Shirley CR, Anderson SJ, Oravecz T.

PLoS One. 2010 Oct 27;5(10):e13654. doi: 10.1371/journal.pone.0013654.

18.

Requirement for class II phosphoinositide 3-kinase C2alpha in maintenance of glomerular structure and function.

Harris DP, Vogel P, Wims M, Moberg K, Humphries J, Jhaver KG, DaCosta CM, Shadoan MK, Xu N, Hansen GM, Balakrishnan S, Domin J, Powell DR, Oravecz T.

Mol Cell Biol. 2011 Jan;31(1):63-80. doi: 10.1128/MCB.00468-10. Epub 2010 Oct 25.

19.

A mouse knockout library for secreted and transmembrane proteins.

Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Solloway M, Parker L, Ye W, Forrest W, Ghilardi N, Oravecz T, Platt KA, Rice DS, Hansen GM, Abuin A, Eberhart DE, Godowski P, Holt KH, Peterson A, Zambrowicz BP, de Sauvage FJ.

Nat Biotechnol. 2010 Jul;28(7):749-55. doi: 10.1038/nbt.1644. Epub 2010 Jun 20.

PMID:
20562862
20.

The adaptor protein Sh2d3c is critical for marginal zone B cell development and function.

Al-Shami A, Wilkins C, Crisostomo J, Seshasayee D, Martin F, Xu N, Suwanichkul A, Anderson SJ, Oravecz T.

J Immunol. 2010 Jul 1;185(1):327-34. doi: 10.4049/jimmunol.1000096. Epub 2010 May 26.

21.

Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate.

Yu XQ, Kramer J, Moran L, O'Neill E, Nouraldeen A, Oravecz T, Wilson AG.

Xenobiotica. 2010 May;40(5):350-6. doi: 10.3109/00498251003611376.

PMID:
20175664
22.

Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.

Jessop TC, Tarver JE, Carlsen M, Xu A, Healy JP, Heim-Riether A, Fu Q, Taylor JA, Augeri DJ, Shen M, Stouch TR, Swanson RV, Tari LW, Hunter M, Hoffman I, Keyes PE, Yu XC, Miranda M, Liu Q, Swaffield JC, David Kimball S, Nouraldeen A, Wilson AG, Foushee AM, Jhaver K, Finch R, Anderson S, Oravecz T, Carson KG.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6784-7. doi: 10.1016/j.bmcl.2009.09.081. Epub 2009 Sep 25.

PMID:
19836232
23.

5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinase.

Tarver JE, Jessop TC, Carlsen M, Augeri DJ, Fu Q, Healy JP, Heim-Riether A, Xu A, Taylor JA, Shen M, Keyes PE, David Kimball S, Yu XC, Miranda M, Liu Q, Swaffield JC, Nouraldeen A, Wilson AG, Finch R, Jhaver K, Foushee AM, Anderson S, Oravecz T, Carson KG.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6780-3. doi: 10.1016/j.bmcl.2009.09.082. Epub 2009 Sep 25.

PMID:
19836229
24.

Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.

Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.

J Med Chem. 2009 Jul 9;52(13):3941-53. doi: 10.1021/jm900278w.

PMID:
19489538
25.

Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions.

Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, Anderson SJ, Sun W, Swaffield J, Oravecz T.

PLoS One. 2009;4(1):e4112. doi: 10.1371/journal.pone.0004112. Epub 2009 Jan 1.

26.

Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint.

Anderson SJ, Lauritsen JP, Hartman MG, Foushee AM, Lefebvre JM, Shinton SA, Gerhardt B, Hardy RR, Oravecz T, Wiest DL.

Immunity. 2007 Jun;26(6):759-72. Epub 2007 Jun 7.

27.

Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes.

Salojin K, Oravecz T.

J Leukoc Biol. 2007 Apr;81(4):860-9. Epub 2007 Feb 8. Review.

PMID:
17289800
28.

Essential role of MAPK phosphatase-1 in the negative control of innate immune responses.

Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T.

J Immunol. 2006 Feb 1;176(3):1899-907.

29.

Chemokine receptor CXCR4-beta1 integrin axis mediates tumorigenesis of osteosarcoma HOS cells.

Miura K, Uniyal S, Leabu M, Oravecz T, Chakrabarti S, Morris VL, Chan BM.

Biochem Cell Biol. 2005 Feb;83(1):36-48.

PMID:
15746965
30.

Protein kinase Cepsilon mediates PMA-induced growth inhibition of low population density NIH 3T3 fibroblasts.

Petrovics G, Bird T, Lehel C, Oravecz T, Anderson WB.

Arch Biochem Biophys. 2002 Jan 15;397(2):217-23.

PMID:
11795874
31.

beta1 Integrin-extracellular matrix protein interaction modulates the migratory response to chemokine stimulation.

Shenoy PS, Uniyal S, Miura K, McColl C, Oravecz T, Morris VL, Chan BM.

Biochem Cell Biol. 2001;79(4):399-407.

PMID:
11527209
32.

Chemical synthesis and characterization of chemokine RANTES and its analogues.

Boykins RA, Oravecz T, Unsworth E, Syin C.

Cytokine. 1999 Jan;11(1):8-15.

PMID:
10080874
34.

A semiautomated fluorescence-based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells.

Pine PS, Weaver JL, Oravecz T, Pall M, Ussery M, Aszalos A.

Exp Cell Res. 1998 Apr 10;240(1):49-57.

PMID:
9570920
35.

Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage.

Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA.

J Exp Med. 1997 Dec 1;186(11):1865-72.

36.

Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans.

Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross MA.

J Immunol. 1997 Nov 1;159(9):4587-92.

PMID:
9379060
37.

Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step.

Oravecz T, Pall M, Norcross MA.

J Immunol. 1996 Aug 15;157(4):1329-32.

PMID:
8759710
38.

CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line.

Oravecz T, Roderiquez G, Koffi J, Wang J, Ditto M, Bou-Habib DC, Lusso P, Norcross MA.

Nat Med. 1995 Sep;1(9):919-26.

PMID:
7585218
39.
40.

Effect of phytohaemagglutinin on CD45 in T cells.

Monostori E, Hartyani Z, Ocsovszky I, Hegedus Z, Oravecz T, Kalman M, Ando I.

Immunol Lett. 1994 Oct;42(3):197-201.

PMID:
7890320
41.

Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA.

J Virol. 1994 Sep;68(9):6006-13.

42.

Novel heterogeneity of the leucocyte common antigen (CD45): disulfide-bound heterodimers between CD45 and an 80 kDa polypeptide.

Oravecz T, Monostori E, Adrian O, Kurucz E, Andó I.

Immunol Lett. 1994 Apr;40(1):7-11.

PMID:
7523290
43.

Immunohistochemical detection of raf protein kinase in cerebral cortical areas of adult guinea pigs and rats.

Mihály A, Endrész V, Oravecz T, Rapp UR, Kuhnt U.

Brain Res. 1993 Nov 12;627(2):225-38.

PMID:
8298966
45.

Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines.

Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, Norcross MA.

AIDS Res Hum Retroviruses. 1993 Feb;9(2):167-74.

PMID:
8096145
46.

CD3-induced T-cell proliferation and interleukin-2 secretion is modulated by the CD45 antigen.

Oravecz T, Monostori E, Kurucz E, Takács L, Andó I.

Scand J Immunol. 1991 Nov;34(5):531-7.

PMID:
1835124
47.

Supplemental Content

Loading ...
Support Center